The TCR-based Therapies Summit is Dedicated to Supercharging TCR Design, Translation & Manufacturing Strategy for Solid Tumor Success
Running digitally for 2021, the 2nd TCR-based Therapies Summit is the leading industry-focused meeting dedicated to supercharging the expanded TCR repertoire through enhanced target specificity, density & binding affinity for solid tumor indications.
This June (8-10), join this exclusive community online to virtually network and learn from the leading experts in pharma, biotech and academia, as we discuss how to how to overcome on-target off-tumor toxicity, enhance the binding affinity and avidity of TCR-T therapies and utilize dual targeting and combination approaches for enhanced efficacy.
Navigate across 3 days packed with dedicated, interactive formats exploring the identification of novel targets, the importance of safety profiling, and discuss optimization of soluble approaches for the development of next-generation TCR-T products.
Helping Deliver Best-In-Class TCR Therapies
Join experts as they discuss the design, efficacy and clinical development of TCR therapeutics for solid tumor indications and beyond.
- Optimize your TCR therapy approach
- Explore novel combination strategies
- Arm your cells against the hostile tumor microenvironment
- Improve target selection and off-target validation
- Explore the future of manufacturing for next-generation TCRs
“Hanson Wade’s CAR-TCR summit has been already the leading specialized conference in the field – what a great suggestion to set up a dedicated forum for the rapidly growing TCR-T area.”
Steffen Walter, Chief Scientific Office, Immatics US
“Hanson Wade’s CAR-TCR summit has been already the leading specialized conference in the field – what a great suggestion to set up a dedicated forum for the rapidly growing TCR-T area.”
Steffen Walter, Chief Scientific Office, Immatics US
“The TCR-based Therapies Summit will be a great forum to learn from and network with leading scientists and companies working to develop T cells as immunotherapy especially for solid tumors.”
Laurence Cooper, Chief Executive Officer, Ziopharm Oncology
World-Class Speaker Faculty
Reno Debets
Professor, Laboratory of Tumor Immunology, Department of Medical Oncology, Chief Scientific Officer
Erasmus MC Cancer Institute, Pan Cancer T B.V.
“TCR-based Therapeutics and their targets are the next frontier in expanding the scope of cancer immunotherapy by providing access to currently undruggable oncogenic proteins."
David A. Scheinberg, Chairman, Molecular Pharmacology, Memorial Sloan Kettering Cancer Center
Proud to Partner With:
